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Antidepressants can increase the spontaneous risk of hypomania or mania when used for treatment in affective
disorders. When prescribed as an antidepressant, bupropion is generally considered to have a lower relative risk
of inducing mood shifts. We describe the case of a 67-year-old man known for dysthymic disorder in remission on
quetiapine and venlafaxine who experienced a first lifetime episode of hypomania with the introduction of bupropion
SR for smoking cessation. To the best of our knowledge, this is the first case report of bupropion-induced mood shift
when used specifically for nicotine cessation in a nonbipolar patient. This case highlights the need for clinicians who
prescribe bupropion for smoking cessation to perform regular and systematic mood follow-ups during treatment.
These follow-ups could even be more important when bupropion is selected to quit smoking in a patient already
taking an antidepressant.
Keywords: Nicotine, Smoking cessation, Bupropion, Antidepressant, Hypomania, VenlafaxineBackground
Bupropion SR is a dopamine/norepinephrine reuptake in-
hibitor licensed for use as a smoking cessation aid. Com-
pared with other antidepressants, bupropion is generally
considered to have a lower relative risk of inducing mood
shifts [1], however there are no controlled studies speci-
fically addressing this risk when prescribed for nicotine
dependence treatment. Secondary mania induction in uni-
polar depression treatment with bupropion has been in-
frequently reported in the literature, but little is known
about the potential for mood shifts when bupropion is
prescribed as a smoking cessation aid. We describe here a
patient who experienced a first lifetime episode of hypo-
mania with the introduction of bupropion SR for smoking
cessation. To the best of our knowledge, this is the first
case report of bupropion-induced mood shift when used
specifically for smoking cessation in a nonbipolar patient.
Case presentation
Mr. X was a 67-year-old man with nicotine dependence (45
packs-years), alcohol dependence in early full remission,
and dysthymic disorder in remission. He was maintained* Correspondence: didier.jutras-aswad@umontreal.ca
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restricted use, distribution, and reproduction ion venlafaxine XR (225 mg per day) and quetiapine XR
(50 mg per day + an additional 25 mg twice daily as needed)
with no recent treatment regimen modification. Past psy-
chiatric history was significant for recurrent unipolar major
depressive episodes and cocaine abuse. Past substance use
history included daily alcohol use since age 35. The number
of standard drinks per day increased over the years but
averaged 14–20 in the two years preceding his sobriety
period. Cocaine was used once per month from the age of
35 to 45 and approximately two times per year thereafter
until his sobriety period. He reported no other recent regu-
lar substance use. The patient had been stable psychiatric-
ally with no alcohol or cocaine use for seven months. There
was no personal or family history of bipolar disorder, but
prior long-term substance use history remains a potential
confounding factor.
For smoking cessation, bupropion SR coupled with nico-
tine replacement therapy (NRT) (14 mg patch daily) and
therapeutic groups were used. In March 2012, bupropion
SR (150 mg per day) was prescribed for three days and a
preplanned quit date was set for day 4. As the treatment
began, the patient noticed some feelings of excitement,
which were amplified when the dose was increased to
150 mg twice daily on the fourth day of treatment. From
that point on, he reported the onset of euphoria, racing
thoughts, and decreased need for sleep. He subsequentlynsee BioMed Central Ltd.Jutras-Aswad This is an open access article distributed
tribution License (http://creativecommons.org/licenses/by/2.0), which permits un-
n any medium, provided the original work is properly cited.
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minimization of the consequences of substance use. He
mentioned no suicidality or psychotic symptoms. The pa-
tient met his therapist during the smoking cessation group
on day 5, who noticed a change in the patient’s affect and
describing him as more anxious, tense, and keyed up. Sub-
jectively, on that day, the patient noticed being more anx-
ious and having less ability to concentrate, which could be
early nicotine withdrawal symptoms or early hypomanic
symptoms. When seen by his psychiatrist 11 days after
treatment initiation, the patient had decided to stop
substance use and bupropion for two days. He was get-
ting back to his baseline level, reporting some residual
anxiety. Venlafaxine and NRT were maintained, while
his quetiapine XR dose was increased to 100 mg per day
regularly; bupropion was discontinued. One week later,
the patient’s mood was stable, and he had not used any
substances.
Discussion
The timing of symptoms suggests an association be-
tween bupropion initiation and mood shift in this pa-
tient. Bupropion can induce mood switches in bipolar
depression, but possibly less frequently than other anti-
depressants [2]. There are only a few cases reported of
bupropion-induced mood shifts in unipolar disorders
and of secondary mania induction [3-5]. To our know-
ledge, bupropion-induced polarity changes in nonbipolar
patients have not been reported during the management
of smoking cessation, except for a case of mania after
abrupt treatment discontinuation [6].
A clinical interaction between bupropion and venlafaxine
could also explain the hypomania. Venlafaxine is a sero-
tonin/norepinephrine reuptake inhibitor. When used as an
adjunct in bipolar depression, it is associated with an in-
creased risk of mood shifts compared with bupropion [1].
An open-label study found a 2.5-fold increase in plasma
levels of venlafaxine when bupropion is added, possibly via
CYP2D6 inhibition [7]. A case series mentioned the need
to decrease venlafaxine dose when bupropion was added
for the treatment of major depressive disorder in order to
diminish serotonergic side-effects [8]. Despite this known
pharmacokinetic interaction, the evidence of its clinical
implication remains limited. Combining therapeutic doses
of these antidepressants with overlapping mechanisms of
action and pharmacokinetic interactions could also en-
hance noradrenergic stimulating effects, which could con-
tribute to the emergence of hypomanic symptoms.
Other contributing factors first include nicotine with-
drawal symptoms, which include irritability, restlessness,
insomnia, anxiety, and poor concentration. Nicotine with-
drawal symptoms could have potentiated or predisposed
the patient to this mood shift. We do not consider the
patient’s substance use to be a contributing factor to hismood shift, since the hypomanic symptoms noticeably
took place before the cocaine/alcohol use. However, his
past substance use disorder could have been a predis-
posing factor, as it has been associated with an increased
risk of antidepressant-induced mania/hypomania in bi-
polar patients [9].
Conclusions
Although there are several hypotheses for the hypomanic
episode, our findings suggest the need to carefully monitor
for mood shifts when bupropion is prescribed as a smoking
cessation aid, even in nonbipolar patients and in particular
when combined with other antidepressants. Smoking ces-
sation represents a sensitive period during which many fac-
tors can alter mood (e.g. nicotine withdrawal, NRT, the
stress of quitting smoking). These factors may modify the
risk of mood shifts associated with bupropion.
Although the benefits of medication-assisted smoking
cessation are clear, there is a need for frequent and system-
atic monitoring of mood symptoms during treatment with
bupropion in the context of smoking cessation, even in pa-
tients not previously diagnosed with bipolar disorder. For
patients who are already receiving antidepressant treat-
ment, selecting bupropion over other smoking-cessation
strategies should take into account the risk of mood shifts
and interactions.
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